Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, is pleased to announce that it has appointed, with immediate effect, Jean-Yves Pavée as a Non-Executive Director; nominated by Abbott (NYSE: ABT).
Jean-Yves Pavée is Senior Vice President, Developed Markets for Abbott’s Established Products Division. He was appointed to his role in July 2013. Previously, he served as Divisional Vice President, EMEA East, and Division Vice President, Pharmaceuticals, Europe South. He joined Abbott in 1992.
Peter Jensen Chairman of Allergy Therapeutics commented:
“We are delighted to welcome Jean-Yves to the Board. He brings extensive industry experience, which will be invaluable to our Company as we continue to execute our global strategy.”
Additional information regarding Jean-Yves Pavée:
Full name and age: Jean-Yves Frédéric Georges André Pavée-Callu, aged 51
There are no further disclosures required under Schedule Two paragraph (g) of the AIM rules.
For further information
Allergy Therapeutics
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
+44 (0) 1903 845 820
Peel Hunt LLP
James Steel
Clare Terlouw
+44 (0) 20 7418 8900
FTI Consulting
Simon Conway
Victoria Foster Mitchell
+44 (0) 20 3727 1000
Note to editors
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging markets Transforming Allergy Treatment
Help employers find you! Check out all the jobs and post your resume.
